This trial is active, not recruiting.

Condition pancreatic cancer
Treatment ccx872-b
Phase phase 1
Target CCR2
Sponsor ChemoCentryx
Start date February 2015
End date January 2017
Trial size 54 participants
Trial identifier NCT02345408, CL002_872


This is an open-label phase 1-b study to evaluate the safety and efficacy of CCX872-B in patients with pancreatic adenocarcinoma also receiving FOLFIRINOX chemotherapy.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
150 mg once or twice daily given orally for at least 12 weeks
Tablets (oral administration)

Primary Outcomes

progression-free survival
time frame: 24 weeks
subject incidence of Grade 3 or 4 adverse events
time frame: 24 weeks

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Histologically or cytologically confirmed non-resectable pancreatic adenocarcinoma with or without metastases - Eastern Cooperative Oncology Group (ECOG) performance status score ≤ 2 - Anticipated life expectancy ≥ 12 weeks - Radiographically measurable disease acc. to RECIST 1.1 - Use of adequate contraception (as described in protocol) - Ability to provide written informed consent and comply with study requirements Exclusion Criteria: - Received other cancer treatment or investigational drug within 4 weeks prior to screening - Women who are pregnant or breastfeeding - Had major surgery within 4 weeks of first dose of study drug - Inadequate liver, renal or bone marrow function within 2 weeks of first dose - Serious concurrent illness, altered medical status or any uncontrolled medical condition - Any infection requiring antibiotic or anti-viral treatment within 4 weeks of screening - Known active HIV, HBV or HCV infection - Inability to swallow tablets - History or presence of any medical condition or disease which, in the opinion of the investigator, may place the subject at unacceptable risk for study participation

Additional Information

Official title An Open-label Phase 1b Study to Evaluate the Safety and Efficacy of CCX872-B in Patients With Pancreatic Adenocarcinoma
Trial information was received from ClinicalTrials.gov and was last updated in June 2016.
Information provided to ClinicalTrials.gov by ChemoCentryx.
Location data was received from the National Cancer Institute and was last updated in June 2016.